NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells

NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation

(2022) Le Shu et al.   ONCOGENE

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer

(2022) Martín Núñez Abad et al.   Cancers

The Exciting New Field of HER2-Low Breast Cancer Treatment

(2021) Daniel Eiger et al.   Cancers

Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis

(2021) Anders Wilder Erickson et al.   npj Breast Cancer

Breast cancer

(2021) Sibylle Loibl et al.   LANCET

Mammary cell gene expression atlas links epithelial cell remodeling events to breast carcinogenesis

(2021) Kohei Saeki et al.   Communications Biology

Evolution of HER2-low expression from primary to recurrent breast cancer

(2021) Federica Miglietta et al.   npj Breast Cancer

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth

(2020) María F. Chervo et al.   ONCOGENE

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

(2020) Antonio Marra et al.   npj Breast Cancer

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

(2019) Udai Banerji et al.   LANCET ONCOLOGY

ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

(2019) Nicolas Kiavue et al.   ONCOGENE

Stem Cells and the Differentiation Hierarchy in Mammary Gland Development

(2019) Naiyang Fu et al.   PHYSIOLOGICAL REVIEWS

Breast cancer

(2019) Nadia Harbeck et al.   Nature Reviews Disease Primers

Early lineage segregation of multipotent embryonic mammary gland progenitors

(2018) Aline Wuidart et al.   NATURE CELL BIOLOGY

Dissecting the mammary gland one cell at a time

(2018) Simona Cristea et al.   Nature Communications

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses

(2017) Darshan S. Chandrashekar et al.   NEOPLASIA

Targeting a cell state common to triple-negative breast cancers

(2015) M. K. Muellner et al.   Molecular Systems Biology

Evaluation of MCF10A as a Reliable Model for Normal Human Mammary Epithelial Cells

(2015) Ying Qu et al.   PLoS One

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines

(2014) HOISEON JEONG et al.   ONCOLOGY REPORTS

Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment

(2014) Mattia Lauriola et al.   Nature Communications

Oncogenic ERBB3 Mutations in Human Cancers

(2013) Bijay S. Jaiswal et al.   CANCER CELL

Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 Activation

(2013) C. Y.-F. Lee et al.   CANCER RESEARCH

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

(2013) G. D. L. Phillips et al.   CLINICAL CANCER RESEARCH

Pertuzumab: new hope for patients with HER2-positive breast cancer

(2012) M. Capelan et al.   ANNALS OF ONCOLOGY

HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation

(2012) D. B. Vaught et al.   CANCER RESEARCH

Modeling ductal carcinoma in situ: a HER2–Notch3 collaboration enables luminal filling

(2011) C-R Pradeep et al.   ONCOGENE

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions

(2011) C-R Pradeep et al.   ONCOGENE

GOBO: Gene Expression-Based Outcome for Breast Cancer Online

(2011) Markus Ringnér et al.   PLoS One

A Perspective on Cancer Cell Metastasis

(2011) C. L. Chaffer et al.   SCIENCE

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

(2010) Sunil Badve et al.   MODERN PATHOLOGY

Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy

(2010) Stuart J Schnitt   MODERN PATHOLOGY

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

(2009) Balazs Györffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

How basal are triple-negative breast cancers?

(2008) François Bertucci et al.   INTERNATIONAL JOURNAL OF CANCER